Acute Myeloid Leukemia Stem Cells: The Challenges of Phenotypic Heterogeneity
Autor: | Martina Konantz, Sarah Bertels, Pauline Hanns, Anna M. Paczulla Stanger, Marlon Arnone, Claudia Lengerke, Parimala Sonika Godavarthy, Maximilian Christopeit |
---|---|
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Cancer Research Immature cells markers Review Disease acute myeloid leukemia Biology leukemic stem cells lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine hemic and lymphatic diseases cellular heterogeneity neoplasms relapse Genetic heterogeneity Clonal hematopoiesis Myeloid leukemia lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Phenotype 030104 developmental biology Oncology 030220 oncology & carcinogenesis Cancer research Stem cell Leukemic Blasts |
Zdroj: | Cancers Cancers, Vol 12, Iss 3742, p 3742 (2020) |
ISSN: | 2072-6694 |
Popis: | Simple Summary Relapse after apparent remission remains a major cause of death in patients with acute myeloid leukemia (AML). On the cellular level, leukemia relapse is considered to emerge from subpopulations of therapy-resistant leukemic stem cells (LSC). Identification and targeting of LSC are thus most important goals for AML treatment. However, AML and their LSC are highly heterogeneous. Here, we review the current knowledge on AML LSC identification and targeting via surface antigens with a focus on heterogeneity among different AML subgroups and genetic backgrounds. Abstract Patients suffering from acute myeloid leukemia (AML) show highly heterogeneous clinical outcomes. Next to variabilities in patient-specific parameters influencing treatment decisions and outcome, this is due to differences in AML biology. In fact, different genetic drivers may transform variable cells of origin and co-exist with additional genetic lesions (e.g., as observed in clonal hematopoiesis) in a variety of leukemic (sub)clones. Moreover, AML cells are hierarchically organized and contain subpopulations of more immature cells called leukemic stem cells (LSC), which on the cellular level constitute the driver of the disease and may evolve during therapy. This genetic and hierarchical complexity results in a pronounced phenotypic variability, which is observed among AML cells of different patients as well as among the leukemic blasts of individual patients, at diagnosis and during the course of the disease. Here, we review the current knowledge on the heterogeneous landscape of AML surface markers with particular focus on those identifying LSC, and discuss why identification and targeting of this important cellular subpopulation in AML remains challenging. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |